Name (Synonyms) | Correlation | |
---|---|---|
drug950 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki | 0.71 |
drug850 | Placebo Wiki | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19. Arm A: CD24Fc/Best Available Treatment; Arm B: placebo/ Best Available Treatment. CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1. Total of 230 subjects will be enrolled and randomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 28 days.
Description: Time to improve in clinical status: the time (days) required from the start of treatment to the improvement of clinical status "severe" to "moderate/mild"; or improvement from "scale 3 or 4" to "scale 5 or higher" based on NIAID ordinal scales.
Measure: Improvement of COVID-19 disease status Time: 14 daysDescription: Time for disease progression from NIAID scale 3 or 4 to scale 2 or 1, and patients need to be on invasive mechanical ventilation, or ESMO, or death.
Measure: Disease progression of COVID-19 Time: 28 daysDescription: All cause of death
Measure: All cause of death Time: 28 daysDescription: Conversion rate of clinical status on days 8 (proportion of subjects who changed from "severe" to "moderate or mild", or the improvement from "scale 3 or 4" to "scale 5 or higher" on NIAID ordinal scale)
Measure: Conversion rate of clinical status at Day 8 Time: 7 daysDescription: Conversion rate of clinical status on days 15 (proportion of subjects who changed from "severe" to "moderate or mild", or the improvement from "scale 3 or 4" to "scale 5 or higher" on NIAID ordinal scale)
Measure: Conversion rate of clinical status at Day 15 Time: 14 daysDescription: The discharge time or NEWS2 (National Early Warning Score 2) of ≤2 is maintained for 24 hours
Measure: Hospital discharge time Time: 28 daysDescription: Duration of mechanical ventilation (IMV, NIV) (days)
Measure: Duration of mechanical ventilation Time: 28 daysDescription: Duration of pressors (days)
Measure: Duration of pressors Time: 28 daysDescription: Duration of extracorporeal membrane oxygenation (days)
Measure: Duration of ECMO Time: 28 daysDescription: Duration of oxygen therapy (oxygen inhalation by nasal cannula or mask) (days)
Measure: Duration of oxygen therapy Time: 28 daysDescription: Length of hospital stay (days)
Measure: Length of hospital stay Time: 28 daysDescription: Changes of absolute lymphocyte count in peripheral blood
Measure: Absolute lymphocyte count Time: 28 days